Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.

Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S.

Sci Rep. 2018 Jul 19;8(1):10902. doi: 10.1038/s41598-018-27643-3.

2.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2018 Jun 26. doi: 10.1093/annonc/mdy207. [Epub ahead of print] No abstract available.

PMID:
29947731
3.

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.

Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.

PMID:
29650750
4.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2017 Oct 1;28(10):2517-2525. doi: 10.1093/annonc/mdx352.

PMID:
28961843
5.

Apremilast in psoriasis - a prospective real-world study.

Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):254-259. doi: 10.1111/jdv.14598. Epub 2017 Oct 12.

PMID:
28925560
6.

The large spectrum of spitzoid tumours: a retrospective survival study.

Broganelli P, Ribero S, Castagno I, Ricceri F, Deboli T, Marra E, Tomasini C, Sacerdote C, Osella-Abate S, Sanlorenzo M, Quaglino P, Fierro MT.

G Ital Dermatol Venereol. 2017 Jul 11. doi: 10.23736/S0392-0488.17.05575-4. [Epub ahead of print]

PMID:
28704985
7.

Fluorescence-advanced videodermatoscopy: a new method for in vivo skin evaluation.

Sanlorenzo M, Vujic I, De Giorgi V, Tomasini C, Deboli T, Quaglino P, Fierro MT, Broganelli P.

Br J Dermatol. 2017 Nov;177(5):e209-e210. doi: 10.1111/bjd.15594. Epub 2017 Oct 27. No abstract available.

PMID:
28421598
8.

Treatment of metastatic melanoma: a multidisciplinary approach.

Fava P, Astrua C, Sanlorenzo M, Ribero S, Brizio M, Filippi AR, Marra E, Picciotto F, Sangiolo D, Carnevale-Schianca F, Aglietta M, Sandrucci S, Ricardi U, Caliendo V, Quaglino P, Fierro MT.

G Ital Dermatol Venereol. 2017 Jun;152(3):241-261. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14. Review.

PMID:
28290625
9.

Role of interferon in melanoma: old hopes and new perspectives.

Sanlorenzo M, Vujic I, Carnevale-Schianca F, Quaglino P, Gammaitoni L, Fierro MT, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2017 Apr;17(4):475-483. doi: 10.1080/14712598.2017.1289169. Epub 2017 Feb 16. Review. Erratum in: Expert Opin Biol Ther. 2018 Mar;18(3):1.

PMID:
28274138
10.

Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich.

Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger K.

J Dtsch Dermatol Ges. 2017 Mar;15(3):309-318. doi: 10.1111/ddg.13191_g.

PMID:
28252852
11.

Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.

Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger K.

J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317. doi: 10.1111/ddg.13191. Epub 2017 Feb 27.

PMID:
28240404
12.

Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.

Kwong A, Sanlorenzo M, Rappersberger K, Vujic I.

Wien Med Wochenschr. 2017 Jan 13. doi: 10.1007/s10354-016-0535-1. [Epub ahead of print]

PMID:
28091975
13.

Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.

Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, Senetta R, Cangemi M, Cattaneo G, Martin V, Coha V, Gallo S, Pignochino Y, Sapino A, Grignani G, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2017 May 1;23(9):2277-2288. doi: 10.1158/1078-0432.CCR-16-1524. Epub 2016 Nov 4.

14.

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.

Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M.

J Am Acad Dermatol. 2016 Oct;75(4):736-739. doi: 10.1016/j.jaad.2016.04.068. Epub 2016 Jul 26.

PMID:
27473452
15.

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.

Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S.

Oncotarget. 2016 Jul 19;7(29):45916-45925. doi: 10.18632/oncotarget.10001.

16.

Efficacy of electrochemotherapy for eruptive legs keratoacanthomas.

Ribero S, Balagna E, Sportoletti Baduel E, Picciotto F, Sanlorenzo M, Fierro MT, Quaglino P, Macripo G.

Dermatol Ther. 2016 Sep;29(5):345-348. doi: 10.1111/dth.12374. Epub 2016 Jun 6.

PMID:
27272980
17.

Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

Posch C, Sanlorenzo M, Vujic I, Oses-Prieto JA, Cholewa BD, Kim ST, Ma J, Lai K, Zekhtser M, Esteve-Puig R, Green G, Chand S, Burlingame AL, Panzer-Grümayer R, Rappersberger K, Ortiz-Urda S.

J Invest Dermatol. 2016 Oct;136(10):2041-2048. doi: 10.1016/j.jid.2016.05.098. Epub 2016 May 29.

18.

Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.

Sanlorenzo M, Vujic I, Posch C, Ma J, Lin K, Lai K, Lee D, Vujic M, Oses-Prieto JA, Chand S, Rodriguez-Peralto JL, Burlingame A, Ortiz-Urda S.

J Proteomics. 2016 Jul 20;144:140-7. doi: 10.1016/j.jprot.2016.05.019. Epub 2016 May 20.

19.

Searching for the Chokehold of NRAS Mutant Melanoma.

Posch C, Vujic I, Monshi B, Sanlorenzo M, Weihsengruber F, Rappersberger K, Ortiz-Urda S.

J Invest Dermatol. 2016 Jul;136(7):1330-1336. doi: 10.1016/j.jid.2016.03.006. Epub 2016 May 7. Review.

20.

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.

Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, Tsumura A, Murphy R, Moy A, Posch C, Monshi B, Rappersberger K, Ortiz-Urda S.

Oncotarget. 2016 Feb 9;7(6):7297-306. doi: 10.18632/oncotarget.6907.

21.

Time-Dependent Measurement of Adverse Events-Reply.

Sanlorenzo M, Vujic I, Ortiz-Urda S.

JAMA Dermatol. 2015 Dec 1;151(12):1392-1393. doi: 10.1001/jamadermatol.2015.3578. No abstract available.

PMID:
26650664
22.

Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review.

Sanlorenzo M, Ribero S, Osella Abate S, Mariani S, Strignano P, Salizzoni M, Savoia P, Fierro MT, Quaglino P.

G Ital Dermatol Venereol. 2015 Oct 20. [Epub ahead of print]

PMID:
26484880
23.

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox.

Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S.

Clin Cosmet Investig Dermatol. 2015 Aug 5;8:423-9. doi: 10.2147/CCID.S87645. eCollection 2015. Review.

24.

Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status: A Systematic Review and Meta-analysis.

Ribero S, Gualano MR, Osella-Abate S, Scaioli G, Bert F, Sanlorenzo M, Balagna E, Fierro MT, Macripò G, Sapino A, Siliquini R, Quaglino P.

JAMA Dermatol. 2015 Dec 1;151(12):1301-1307. doi: 10.1001/jamadermatol.2015.2235.

PMID:
26332402
25.

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S.

JAMA Dermatol. 2015 Nov;151(11):1206-1212. doi: 10.1001/jamadermatol.2015.1916.

26.

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

Sanlorenzo M, Vujic I, Moy A, Quaglino P, Fierro MT, Gammaitoni L, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Expert Opin Biol Ther. 2015;15(10):1491-500. doi: 10.1517/14712598.2015.1069272. Epub 2015 Jul 24. Review.

27.

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.

Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S.

J Invest Dermatol. 2015 Oct;135(10):2475-2483. doi: 10.1038/jid.2015.198. Epub 2015 May 27.

28.

Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group.

Quaglino P, Fava P, Caproni M, Antiga E, De Simone C, Papini M, Parodi A, Novelli M, Osella-Abate S, Ribero S, Sanlorenzo M, Ponti R, Fierro MT, Marzano AV, Savoia P.

J Eur Acad Dermatol Venereol. 2016 Apr;30(4):655-8. doi: 10.1111/jdv.13100. Epub 2015 Mar 24.

29.

Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome.

Sanlorenzo M, Osella-Abate S, Ribero S, Marenco F, Nardò T, Fierro MT, Novelli M, Cervetti O, Bernengo MG, Quaglino P.

Int J Dermatol. 2015 Sep;54(9):1023-9. doi: 10.1111/ijd.12730. Epub 2015 Feb 6.

30.

Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.

Posch C, Latorre A, Crosby MB, Celli A, Latorre A, Vujic I, Sanlorenzo M, Green GA, Weier J, Zekhtser M, Ma J, Monico G, Char DH, Jusufbegovic D, Rappersberger K, Somoza Á, Ortiz-Urda S.

Biomed Microdevices. 2015 Feb;17(1):15. doi: 10.1007/s10544-014-9908-7.

31.

The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes.

Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S.

JAMA Dermatol. 2015 Apr;151(4):450-2. doi: 10.1001/jamadermatol.2014.4643. No abstract available.

32.

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K, Ortiz-Urda S.

Oncotarget. 2015 Jan 20;6(2):969-78.

33.

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.

J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16.

34.

Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?

Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, Macripò G, Macrì L, Sapino A, Quaglino P.

Ann Surg Oncol. 2015;22(6):1967-73. doi: 10.1245/s10434-014-4211-7. Epub 2014 Nov 12.

35.

Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years.

Osella-Abate S, Ribero S, Sanlorenzo M, Maule MM, Richiardi L, Merletti F, Tomasini C, Marra E, Macripò G, Fierro MT, Quaglino P.

Int J Cancer. 2015 May 15;136(10):2453-7. doi: 10.1002/ijc.29281. Epub 2014 Oct 30.

36.

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.

Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM.

Oncotarget. 2014 Sep 15;5(17):7936-44.

37.

The risk of melanoma in airline pilots and cabin crew: a meta-analysis.

Sanlorenzo M, Wehner MR, Linos E, Kornak J, Kainz W, Posch C, Vujic I, Johnston K, Gho D, Monico G, McGrath JT, Osella-Abate S, Quaglino P, Cleaver JE, Ortiz-Urda S.

JAMA Dermatol. 2015 Jan;151(1):51-8. doi: 10.1001/jamadermatol.2014.1077. Review.

38.

Prognostic differences across sexes in melanoma patients: what has changed from the past?

Sanlorenzo M, Ribero S, Osella-Abate S, Zugna D, Marenco F, Macripò G, Fierro MT, Bernengo MG, Quaglino P.

Melanoma Res. 2014 Dec;24(6):568-76. doi: 10.1097/CMR.0000000000000093.

39.

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics.

Latorre A, Posch C, Garcimartín Y, Celli A, Sanlorenzo M, Vujic I, Ma J, Zekhtser M, Rappersberger K, Ortiz-Urda S, Somoza Á.

Nanoscale. 2014 Jul 7;6(13):7436-42. doi: 10.1039/c4nr00019f.

PMID:
24882040
40.

Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature.

Vujic I, Shroff A, Grzelka M, Posch C, Monshi B, Sanlorenzo M, Ortiz-Urda S, Rappersberger K.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):595-8. doi: 10.1111/jdv.12392. Epub 2014 Feb 17. Review.

PMID:
24665876
41.

Melanoma immunotherapy.

Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S.

Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20. Review.

42.

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.

Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K.

Br J Cancer. 2014 Mar 18;110(6):1427-32. doi: 10.1038/bjc.2014.62. Epub 2014 Feb 11.

43.

Melanoma in patients younger than 20 years.

Sanlorenzo M, Ribero S, Osella-Abate S, Balagna EM, Caliendo V, Macripò G, Bernengo MG, Quaglino P.

G Ital Dermatol Venereol. 2013 Dec;148(6):667-72.

PMID:
24442049
44.

Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients.

Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G, Tomasini C, Senetta R, Macripò G, Bernengo MG, Quaglino P.

Br J Dermatol. 2013 Dec;169(6):1240-5. doi: 10.1111/bjd.12586.

PMID:
23952011
45.

Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes.

Ribero S, Quaglino P, Osella-Abate S, Sanlorenzo M, Senetta R, Macrì L, Savoia P, Macripò G, Sapino A, Bernengo MG.

J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1132-7. doi: 10.1111/j.1468-3083.2012.04677.x. Epub 2012 Sep 23.

46.

[Leprosy surgery in a bush hospital in Africa: experience in Madagascar].

Sanlorenzo M, Rakotondrajao J, Caldera D, Bellato C.

Acta Leprol. 2000-2001;12(1):19-24. French.

PMID:
11526637
47.

[Autoperfusion of ascitic fluid: 38 cases].

Sanlorenzo M, Caldera D, Rakotondrajao J, Randremanana J, Razanadranaivo F.

Arch Inst Pasteur Madagascar. 1993;60(1-2):69-71. French.

PMID:
8192545
48.

[Schistosoma mansoni morbidity in a region of the south of Madagascar: preliminary data].

Sanlorenzo M, Donatella C, Rakotondrajao J, Razanadranaivo F, Andrianaja V.

Arch Inst Pasteur Madagascar. 1993;60(1-2):35-7. French.

PMID:
8192538
49.

[Wandering spleen. Considerations on 2 clinical cases].

Perinotti R, Sanlorenzo M, Rosso G.

Minerva Med. 1992 Dec;83(12 Suppl 1):79-82. Italian. No abstract available.

PMID:
1300478
50.

[Cutaneous neoplasms during leprosy: 2 case reports].

Sanlorenzo M, Ratrimoarivony C, Caldera D, Rakotondrajao J, Mounden JC.

Acta Leprol. 1992;8(2):105-7. French.

PMID:
1293912

Supplemental Content

Loading ...
Support Center